The U.S. Supreme Court on Wednesday extended a stay on limits to a federally approved abortion drug, giving the panel two more days to consider a case that could determine whether the widely used medication can remain on the market.
The stay, now in place until the end of Friday, was due to end at midnight amid an unprecedented case testing the Food and Drug Administration’s authority to approve and regulate drugs.
A Texas district court judge earlier this month ordered the pill, called mifepristone, off the market, arguing that the FDA acted hastily when it approved the medicine more than two decades ago. An appeals court last week said the pill could remain available, but barred providers from sending mifepristone through the mail.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect